The Joint Committee on Vaccination and Immunisation has recommended that all UK teenagers receive the meningitis B vaccine on the NHS. This follows outbreaks that exposed the limits of previous calculations about cost and carriage.
On 16 July 2026 the committee published its statement. It calls for one dose at around age 15 for those who received the vaccine as infants, born on or after 1 May 2015. For unprimed adolescents born on or before 30 April 2015 it backs a two-dose schedule. Catch-up programmes are also supported for cohorts who missed the infant programme.
These steps come after the Kent outbreak earlier in 2026, the largest and fastest-growing MenB outbreak recorded in the UK. It produced 29 confirmed or suspected cases and two deaths. A separate incident in Berkshire in May took a school student's life. Invasive meningococcal disease remains rare. Yet its impact can devastate families in ways no spreadsheet fully captures.
Invasive meningococcal disease is a rare but very serious illness, which can have a devastating impact on lives. JCVI has worked closely with meningitis charities and would like to thank all those who responded, including on behalf of loved ones who sadly died or had life-changing complications. Their lived experiences were carefully considered.
Prof Wei Shen Lim, JCVI chair, spoke with quiet recognition of that reality. The committee had reviewed evidence again after the outbreaks. A time-limited one-off two-dose programme is already under way this summer for eligible 17- and 18-year-olds and those under 25 starting university. Lim noted the sequence clearly.
Following the meningitis outbreaks in early 2026, a one-off programme for 2-doses of MenB vaccine is being offered to eligible young people this summer. Additionally, JCVI has now also provided Government with a recommendation for a future routine MenB adolescent vaccination programme.
Teenagers and young adults sit at higher risk because of close-contact settings in schools and universities. The infant programme introduced in 2015 proved highly effective, yet protection wanes. Previous JCVI assessments judged a routine adolescent programme not cost-effective. Recent events forced a sharper look at real-world consequences.
The recommendation now sits with ministers in each UK nation. Implementation will test the NHS's capacity to act without the bureaucratic drift that so often blunts public health measures. Families who have buried children or watched them endure permanent harm deserve more than another review. They need swift rollout that respects parental judgment and puts protection first.
